Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider Jay Barth sold 5,000 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $13.59, for a total transaction of $67,950.00. Following the sale, the insider now directly owns 69,184 shares in the company, valued at $940,210.56. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) traded down $0.23 during mid-day trading on Tuesday, hitting $12.51. 2,193,572 shares of the stock were exchanged, compared to its average volume of 3,185,740. The company has a current ratio of 6.32, a quick ratio of 6.22 and a debt-to-equity ratio of 0.39. Amicus Therapeutics, Inc. has a 12 month low of $4.41 and a 12 month high of $16.60.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). The firm had revenue of $10.90 million during the quarter, compared to the consensus estimate of $9.02 million. Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The firm’s revenue for the quarter was up 419.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.33) earnings per share. equities analysts forecast that Amicus Therapeutics, Inc. will post -1.56 earnings per share for the current year.

FOLD has been the topic of several analyst reports. Leerink Swann reissued an “outperform” rating and set a $17.00 price target (down from $18.00) on shares of Amicus Therapeutics in a research report on Saturday, September 16th. Goldman Sachs Group reissued a “neutral” rating and set a $17.00 price target on shares of Amicus Therapeutics in a research report on Friday, October 6th. Zacks Investment Research raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research report on Tuesday, October 10th. Chardan Capital reissued a “buy” rating and set a $16.50 price target (down from $17.50) on shares of Amicus Therapeutics in a research report on Wednesday, September 13th. Finally, Bank of America boosted their price target on shares of Amicus Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, October 4th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $17.81.

Several hedge funds have recently modified their holdings of FOLD. Strs Ohio bought a new stake in shares of Amicus Therapeutics in the 3rd quarter valued at about $102,000. Teacher Retirement System of Texas raised its holdings in shares of Amicus Therapeutics by 1.7% in the 2nd quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 169 shares during the period. Tudor Investment Corp ET AL bought a new stake in shares of Amicus Therapeutics in the 2nd quarter valued at about $124,000. Aperio Group LLC raised its holdings in shares of Amicus Therapeutics by 13.5% in the 2nd quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 1,663 shares during the period. Finally, Zacks Investment Management bought a new stake in shares of Amicus Therapeutics in the 2nd quarter valued at about $145,000.

ILLEGAL ACTIVITY WARNING: “Jay Barth Sells 5,000 Shares of Amicus Therapeutics, Inc. (FOLD) Stock” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/05/jay-barth-sells-5000-shares-of-amicus-therapeutics-inc-fold-stock.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.